Clinical outcomes of prexasertib monotherapy in recurrent <i>BRCA</i> wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses.

Moreover, the presence of >30% TIL was seen only in patients who experienced a clinical benefit (25% vs 0%, p=0.22) and the tumors of patients who experienced a clinical benefit from therapy showed a trend towards greater TIL compared with those who lacked clinical benefit (27% vs 11%, p=0.07), suggesting TIL levels may serve as both a prognostic and possibly predictive biomarker, requiring further validation ( online supplemental figure 2 ).

also in 53,322 other papers